Park Ha Biological Technology Co. Ltd. (Class A) (BYAH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, BYAH scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

• Fundamental Cash Engine: 14 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 1.09%. Per the SEC financials, FY 2025 net income was $-24.4M against revenue of $2.5M, while FCF was $0.1M. Modest free cash flow relative to a deeply negative earnings line is the central tension in this pillar.
• Whale / 13F Flow: 5 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the weakest pillar relative to its weight, signaling limited institutional sponsorship in the source data.
• Insider Conviction: 7 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and Congressional flow does not offer meaningful conviction support.
• Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 and the score reflects sector sensitivity. A beta of 1.0 means the stock moves in line with the broader market rather than offering defensive or amplified exposure.
• Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 5/9, and Debt/Equity is 0.5. This is the strongest pillar, though it still reflects only middling financial health.

For a prospective investor evaluating the stock today, the rating points to a weak operating picture: negative operating and net margins, zero ROIC, and a thin free-cash-flow yield. The upside case would need to rest on a reversal in operating results, which the source data does not evidence. The most constructive element is the balance-sheet pillar; the most concerning is the absence of institutional and insider conviction.

Per the profile, Park Ha Biological Technology Co. Ltd. (Class A) is a NASDAQ-listed issuer in the Consumer Discretionary sector and the Package Goods/Cosmetics industry. The profile identifies its market capitalization as $0.0B. The source data does not describe specific products, customer segments, or revenue model beyond the sector and industry classification. Per the market data, gross margin is 94.4%, with operating margin at -60%.

Per the SEC financials, revenue was broadly stable across the three reported periods, while operating and net income swung from positive in FY 2023 and FY 2024 to substantially negative in FY 2025. Per the market data, operating and net margins are both -60%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.5. The forensic pillar score of 11 / 20 reflects this middling balance-sheet posture.

Per the recent news and catalysts section, six items reference BYAH, each sourced from aggregator or research outlets (Moomoo, TradingView, Yahoo Finance UK, Timothy Sykes, StocksToTrade, and Yahoo! Finance Canada). Each is labeled "MARKET WIRE" with a YELLOW signal light. The headlines describe general stock-forecast, estimates, seasonal-returns, and volatility coverage; none identifies a specific company event such as earnings, a contract, or a regulatory action. One item references Longevity Health Holdings, Inc. (XAGE) in its headline, though it is tagged to BYAH. Risk watch: the 52-week range of $1.9 to $158 is extremely wide and the volume of 2204 is low, both of which the source data reports without further explanation. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. The source data therefore does not establish supplier concentration, customer dependency, or cross-sector correlation for BYAH. A prospective investor should note that the absence of mapped links means second-order effects cannot be evaluated from these sources. The only sector-level data point is the classification itself: Consumer Discretionary / Package Goods/Cosmetics.

• What drove the swing from positive net income of $0.9M (FY 2023) and $0.5M (FY 2024) to a net loss of $-24.4M in FY 2025?
• What are the company's cash and debt balances, which the source data lists as N/A?
• Why is the 52-week range $1.9 to $158, and what events account for that magnitude of price movement?
• What are the company's specific products, customers, and revenue drivers within Package Goods/Cosmetics?
• What are the forward earnings expectations, given that analyst data is absent?